Alnylam has clearly exceeded expectations. 🚀
🟢 What makes the results better than expected
- Sales growth: Total product sales increased by 64 % to USD 672 million compared to the previous year - this is well above the previous growth trend.
- AMVUTTRA success: Turnover with AMVUTTRA increased by 114 % to 492 million USD - a huge leap which, according to the CEO, represents a "significant turning point" in the TTR franchise.
- Forecast increase: Alnylam has raised its sales forecast for the full year by USD 575 million upwards - a clear sign that the company has outperformed itself.
- Positive study results: New data from clinical trials (e.g. HELIOS-B and TRITON-CM) strengthen the outlook for future growth.
- Marketing authorizations: AMVUTTRA has been approved in EU, UK, Brazil and Japan for a new indication (ATTR-CM) - this creates further sales potential.
📊 Although the non-GAAP results were slightly below the previous year's figure, growth and demand were so strong that the company confirmed its profitability targets for 2025.
🧬 Alnylam Pharmaceuticals: Quarterly report Q2 2025 - Highlights at a glance
Here are the key points from Alnylam Pharmaceuticals' latest press release:
📈 Financial results Q2 2025
- Total revenue: USD 773 million (+17% compared to Q2 2024)
- Product sales: USD 672 million (+64 %)
- AMVUTTRA® (vutrisiran): USD 492 million (+114 %)
- ONPATTRO® (patisiran): USD 53 million (-32 %)
- GIVLAARI® (givosiran): USD 81 million (+30 %)
- OXLUMO® (lumasiran): USD 47 million (+15 %)
- Collaborations: USD 61 million (-73 %)
- Royalty sales: USD 40 million (+78 %)
💊 Clinical and regulatory progress
- Approval of AMVUTTRA for ATTR-CM in EU, Brazil, UK and Japan
- Start of the TRITON-CM Phase 3 trial with Nucresiran
- New clinical trials planned for:
- Zilebesiran (cardiovascular diseases)
- Nucresiran (hATTR-PN)
- Mivelsiran (Alzheimer's disease)
📊 Forecast for the full year 2025
- Increased sales forecast:
- TTR franchise: $2.175-2.275 million
- Total product revenue: $2,650-2,800m → +27% compared to previous forecast
- Target: Achieve profitability
🧪 Research & pipeline
- Alzheimer's therapy Mivelsiran shows positive Phase 1 results
- Phase 1 started for ALN-4324 for the treatment of type 2 diabetes
- Progress in partnerships with Regeneron, Roche, Agios, Sanofi
*created with AI
